Reported 7 months ago
In this Motley Fool article, the debate on whether it's too late to buy Pfizer stock is discussed. Critics highlight issues like declining revenue and recent losses, suggesting a decline, but supporters point to Pfizer's R&D capabilities, acquisitions, and strategic plans for growth. With a focus on expanding its oncology pipeline and revenue expectations, Pfizer's future outlook remains optimistic, providing potential for significant returns for patient investors. The article concludes that despite some challenges, it's not too late to invest in Pfizer stock.
Source: YAHOO